Vaccine plus pembrolizumab for breast cancer in the brain
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to receive the study cancer treatment if you’re not pregnant and not breastfeeding
- You must have breast cancer that is either triple-negative or HER2+ (based on lab testing of your tumor)
- You must have measurable brain metastases that meet the trial’s size and stability rules
- You must have good enough blood counts, liver/kidney tests, and overall functioning (ECOG 0 or 1)
- Any brain-related symptoms must be controlled, and steroid use for brain swelling must be low (10 mg prednisone or less per day)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
This trial tests a new type of vaccine (dendritic cells) injected directly into the spinal fluid, combined with either trastuzumab (if your breast cancer is HER2-positive) or nivolumab (if your breast cancer is HER2-negative). The goal is to see if this combination can better control breast cancer that has spread to the lining of the brain and spinal cord.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.